Avacta Group plc (AVCT) Ordinary Shares 10p
Avacta Group plc Ordinary Shares 10p
- Type:
- Miscellaneous
- Shareholder action required:
- Yes
- Status:
- Update Pending
- Add to watchlist
- Create an alert
- This stock can be held in a
Avacta Group plc Ordinary Shares 10p
- Type:
- Miscellaneous
- Shareholder action required:
- Yes
- Status:
- Update Pending
Avacta Group plc Ordinary Shares 10p
- Type:
- Miscellaneous
- Shareholder action required:
- Yes
- Status:
- Update Pending
Business summary
Avacta Group plc is a life sciences company. The Company is focused on improving people's health and well-being through targeted oncology drugs and powerful diagnostics. It has two divisions: Diagnostics and Therapeutics. Its therapeutics division, which is a clinical-stage oncology drug developer, is building a wholly owned pipeline of novel Affimer immunotherapies and prelCISION tumour-targeted chemotherapies. Its lead program, AVA6000, is a prelCISION tumour-targeted form of the established chemotherapy doxorubicin. Its Affimer platform is a class of biotherapeutics based on a naturally occurring human protein. The Company’s prelCISION targeted chemotherapy platform releases active chemotherapy in the tumor, which limits the systemic exposure that causes damage to healthy tissues and thereby improves the overall safety and therapeutic potential of these anti-cancer treatments. The Company’s Diagnostics Division develops and supplies a range of in-vitro diagnostic (IVD) solutions.
Contact details
Important dates
General stock information
- EPIC:
- AVCT
- ISIN:
- GB00BYYW9G87
- Market cap:
- £174.38 million
- Shares in issue:
- 350.51 million
- Sector:
- Pharmaceuticals & Biotechnology
- Exchange:
- London Stock Exchange
- Currency:
- Sterling pence
- Indices:
- FTSE AIM 100,FTSE AIM All Share
Key personnel
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.